Cftr Trikafta denied as non-formulary by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for cftr trikafta are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Denies Trikafta as Non-Formulary

Blue Cross Blue Shield formularies (drug lists) are tiered, and specialty drugs like this CFTR modulator combination are frequently placed on a non-preferred or excluded tier. A non-formulary denial means the plan will not cover the drug at standard cost-sharing under the current formulary. However, non-formulary status does not mean the drug is unavailable — plans must provide a formulary exception process, and cystic fibrosis patients often succeed in obtaining coverage through that route or on appeal.

## Your Federal Appeal Rights

Under ACA §2719, plans must offer a formulary exception or appeals process. Under ERISA §503, employer plans must provide full-and-fair review. You have 180 days from the denial to file an internal appeal. After an internal denial, you may request independent external review — typically within four months of that decision. Expedited review is available when delay would jeopardize health or ability to regain function.

## The Concrete Appeal Process

1. Request a formulary exception — this is a separate, often faster pathway than the standard grievance. Ask BCBS for its formulary exception request form. 2. Simultaneously or as a follow-up, file a formal internal appeal citing medical necessity for the non-formulary agent. 3. If denied, escalate to external independent review. 4. Check whether your state insurance commissioner requires additional consumer protections for specialty drug access.

## Documentation to Gather

• Prescriber letter explaining formulary exception need: the letter should state why no formulary-listed alternative is clinically appropriate for this patient's specific confirmed CFTR genotype
• Confirmed CFTR genotype report — some formulary alternatives are only approved for different mutation profiles; genotype specificity is often the key argument
• Clinical notes documenting disease severity, current functional status, and pulmonary trajectory
• History of any formulary alternatives tried, with dates and documented outcomes or reason they are not indicated
• FDA prescribing label highlighting the approved indication relevant to this patient's genotype

## Criteria-Mapping Structure

Obtain BCBS's published formulary exception criteria and its current non-formulary coverage policy. Build a side-by-side response:

| Exception Criterion | Patient-Specific Evidence | |---|---| | Formulary alternative not clinically appropriate | Genotype incompatibility or prior failure documentation | | Medical necessity for non-formulary agent | Prescriber letter + clinical notes | | FDA indication applies to this patient | Label excerpt + confirmed genotype |

Address every listed exception criterion directly. The strongest single argument is typically genotype specificity: if the plan's formulary alternatives are not FDA-approved for this patient's mutation profile, that distinction — documented precisely — often resolves non-formulary denials at the exception or first internal appeal stage.